Semaglutide lowered the rate of major heart problems by about a third across the trials that tested it. The same pooled data put a number on what that protection costs.
A meta-analysis published June 12 in Biomedical Reports ↗ combined 11 randomized trials covering 25,067 people on semaglutide or a comparison treatment, and found the drug cut major adverse cardiovascular events by 32 percent (odds ratio 0.68, 95 percent confidence interval 0.52 to 0.91). Major adverse cardiovascular events, or MACE, is the standard bundle clinicians track: heart attack, stroke, and death from heart causes. Semaglutide is the molecule sold as Ozempic for diabetes and Wegovy for weight loss.
We have written before that GLP-1 drugs cut heart events even in people who are not obese ↗. This analysis does something narrower and more useful. It isolates semaglutide on its own, and it checks whether the benefit survives once you pull out the trials that might be carrying it.
It does. When the authors removed the STEP obesity trials, the estimate barely moved (odds ratio 0.70). When they removed both heart-failure trials, the same thing (0.66). No single block of studies was propping up the headline number, which is the first thing a skeptic checks in a pooled result.
The benefit is not flat
The single number hides a slope. A meta-regression, which hunts for trial-level features that track with larger or smaller effects, found semaglutide helped more in patients who started lighter and with lower LDL and total cholesterol, and helped less as age, HbA1c (a measure of average blood sugar over months), and blood pressure climbed (every one of those links at p below 0.01). That runs against the easy assumption that the sickest patients always have the most to gain. Here the cleaner cardiovascular profile a patient walked in with, the more the drug seemed to add.
The protection is not free
Pool the safety data and the other side of the ledger appears. Semaglutide raised the risk of any gastrointestinal problem by 47 percent (relative risk 1.47), more than doubled gallbladder events (2.37), and more than doubled the chance a patient quit the drug because of gut side effects (2.32). For a reasonably healthy person taking the drug to head off a heart attack years down the line, a gallbladder removal is a real entry on the cost side, not a footnote.
Two cautions sit on top of the whole thing. Seven of the 11 trials enrolled at least three-quarters white participants, and none came from low-income countries, so the pooled effect speaks loudest for the population already best represented in cardiovascular research. And an odds ratio built from pooled trials is an average across different doses, durations, and patient mixes. It tells you the direction is solid. It does not promise the exact size in any one clinic.
Semaglutide on our platform ↗ acts on the GLP-1 receptor ↗, and the cardiovascular signal is now among the most replicated findings attached to that receptor across our coverage. The new wrinkle is that the price tag showed up in the same table as the benefit, rather than in a separate safety paper most readers never reach.
The heart benefit is real and it is large. The honest way to read this analysis is that semaglutide buys you fewer heart attacks and sells you a rougher gut, and most patients who qualify will still take that trade.